Publicaciones en colaboración con investigadores/as de Massachusetts General Hospital (10)

2024

  1. Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study

    Future oncology (London, England), Vol. 20, Núm. 6, pp. 297-306

2023

  1. Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

    Annals of Oncology, Vol. 34, Núm. 2, pp. 173-185

  2. Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817

    Journal of Thoracic Oncology, Vol. 18, Núm. 1, pp. 79-92

2022

  1. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

    Annals of Oncology, Vol. 33, Núm. 5, pp. 466-487

  2. Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

    Annals of Oncology, Vol. 33, Núm. 11, pp. 1168-1178

2021

  1. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

    The Lancet Oncology, Vol. 22, Núm. 7, pp. 959-969

2018

  1. Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials

    Clinical Lung Cancer, Vol. 19, Núm. 4, pp. e465-e479

2015

  1. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer

    New England Journal of Medicine, Vol. 373, Núm. 2, pp. 123-135

2012

  1. Maintenance treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology

    Lung Cancer, Vol. 76, Núm. 3, pp. 269-279

2001

  1. Genitourinary malignancies.

    Cancer chemotherapy and biological response modifiers, Vol. 19, pp. 573-595